Alexion

R&D Roundup: Pharma gets in on the biotech boom

https://pharmaphorum.com/r-d/views-analysis-r-d/rd-roundup-pharma-gets-in-on-the-biotech-boom/

A lifeline for rare disease patients

https://deep-dive.pharmaphorum.com/magazine/pharma-research-rare-diseases/alexion-sean-richardson-charles-de-wet/

Alexion signs R&D deals with two Nordic biotechs

https://pharmaphorum.com/news/alexion-signs-rd-deals-with-two-nordic-biotechs/

Alexion aims for fourth rare disease use for blockbuster Soliris

https://pharmaphorum.com/news/alexion-aims-for-fourth-rare-disease-use-for-blockbuster-soliris/

Alexion joins with Dicerna to develop RNAi therapies for complement diseases

https://pharmaphorum.com/news/alexion-joins-with-dicerna-to-develop-rnai-therapies-for-complement-diseases/

Alexion buys rare diseases biotech Syntimmune for up to $1.2bn

https://pharmaphorum.com/news/alexion-buys-rare-diseases-biotech-syntimmune-for-up-to-1-2bn/

Alexion prepares filings for new rare disease use for Soliris

https://pharmaphorum.com/news/alexion-prepares-filings-for-new-rare-disease-use-for-soliris/

Alexion hastens review of successor to rare disease blockbuster Soliris

https://pharmaphorum.com/news/alexion-hastens-review-of-successor-to-rare-disease-blockbuster-soliris/

Alexion’s Soliris successor aces two phase 3 trials

https://pharmaphorum.com/news/alexions-soliris-successor-aces-two-phase-3-trials/

1 2 3

Close in 10 seconds

Pharmaphorum.com

Search